Ambys Medicines garners $140 million to develop chronic liver disease treatments
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.
CLD
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.